Humacyte Unveils Hospital Cost Data Highlighting Expense of Treating Preventable Extremity Arterial Injuries
DURHAM, N.C., January 08, 2026 (GLOBE NEWSWIRE) - Humacyte, Inc. (Nasdaq: HUMA), has announced findings from a comprehensive five-year analysis focusing on hospital charges related to extremity arterial injuries and their complications.
Key Findings from the Analysis
The analysis evaluated hospital charges and healthcare resource utilization involving 964 adult patients with extremity arterial injuries that necessitated surgical repair. The critical data reveals:
- The average hospital charge for extremity arterial injury repair is $316,600 per patient.
- Complications such as amputation and conduit infection can lead to additional costs of approximately $492,986 and $589,921 per patient, respectively.
- The average reimbursed cost for these patients was reported to be $75,947.
Impact of Preventable Complications
Preventable complications, notably graft infection and amputation, have been shown to significantly inflate hospital charges. This underscores the potential economic burden on healthcare systems stemming not from the initial injury but rather the secondary issues resulting from it.
The study found that:
- Vascular graft infections added an average of $589,921 to hospital charges, with an average reimbursement of $84,598.
- Amputation contributed to an additional $492,986 in hospital charges, with average reimbursements reaching $116,611.
Symvess®: A Solution for Severe Vascular Injuries
Humacyte’s Symvess (acellular tissue engineered vessel) was included in the analysis as a potential alternative for patients unable to receive vein graft repairs. Statistical evidence suggests that the use of Symvess may not only reduce the rates of complications but could also significantly lower costs associated with extremity arterial injury repairs.
In previous clinical evaluations, Symvess has demonstrated:
- A one-ninth rate of infection compared to historical controls based on synthetic grafts.
- An amputation rate one-fifth that of previous historical controls.
Expert Insights
Fulton Velez, MD, MS, MBA, Humacyte's Head of Field Value & Market Access, emphasized the implications of the study results, stating: "The high costs often stem not from the initial injury, but rather from preventable complications. For a sizeable portion of patients who cannot be repaired using their own vein, Symvess could help mitigate these expensive complications, ultimately saving healthcare dollars while enhancing patient outcomes."
Regulatory Indications and Safety Information
Symvess is indicated as a vascular conduit for urgent revascularization in adults facing extremity arterial injury when autologous vein grafting is not feasible. However, the product comes with critical safety information, including:
- Graft failure risks such as mid-graft rupture leading to life-threatening hemorrhage.
- Thrombosis risks if antiplatelet therapy is discontinued.
- Possible transmission of infectious diseases due to the cellular components used in its manufacture.